Expanding into New Markets: The Pharmacovigilance Challenges Pharma Companies Meet

Introduction 

Expanding a pharmaceutical product into a new country can open significant opportunities for growth, but market entry is not simply a regulatory submission or commercial decision. Once a medicinal product becomes available to patients in a new market, the Marketing Authorisation Holder (MAH) takes on a new set of pharmacovigilance (PV) responsibilities that must be understood, implemented, and maintained throughout the product lifecycle. 

Pharmacovigilance is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects and other medicine-related problems. Its importance extends beyond individual adverse event reporting: an effective PV system enables companies and health authorities to continuously evaluate whether the benefits of a medicine continue to outweigh its risks. 

The challenge is that pharmacovigilance requirements are not globally identical. While international standards such as those developed by the International Council for Harmonisation (ICH) provide an important foundation, each market may impose additional national requirements concerning local contacts, reporting timelines, safety databases, literature monitoring, risk management, periodic reporting, safety agreements, and communication with national competent authorities. 

Therefore, successful market expansion requires companies to treat pharmacovigilance as an integral part of their market-entry strategy, rather than as an activity that begins after commercialisation. 

1. Understanding the Pharmacovigilance Landscape Before Market Entry

One of the first challenges for a pharmaceutical company entering a new market is understanding what the local pharmacovigilance system actually requires. 

A company may already have an established global PV system, including procedures for Individual Case Safety Reports (ICSRs), signal management, periodic safety reporting, risk management, and literature monitoring. However, these global processes may not automatically satisfy the requirements of a new jurisdiction. 

Before launch, the company should conduct a country-specific PV gap assessment covering areas such as: 

• Pharmacovigilance legislation and national guidelines 

• Regulatory authority requirements 

• MAH responsibilities 

• Local PV contact or Local Person Responsible for Pharmacovigilance requirements 

• QPPV or global PV oversight requirements, where applicable 

• ICSR reporting timelines and submission methods 

• Local safety database requirements 

• Local literature monitoring 

• Risk management requirements 

• Periodic safety reporting 

• Signal detection and management 

• Safety communication requirements 

• Pharmacovigilance inspections 

• Record retention requirements 

• Language and translation requirements 

• Requirements for agreements with distributors, affiliates, licensees, or service providers 

This assessment should ideally be completed before the marketing authorisation is granted or before the product is launched, allowing sufficient time to establish the required PV infrastructure. 

For example, in the European Union, MAHs are required to operate a pharmacovigilance system, and the system must be supported by an adequate quality system. EU requirements also provide for a Qualified Person Responsible for Pharmacovigilance (QPPV) and a Pharmacovigilance System Master File (PSMF). 

The key lesson is simple: a global PV system provides the foundation, but local requirements determine how that system must operate in each market. 

2. Establishing Local Pharmacovigilance Responsibilities

Entering a new market often means determining who is legally and operationally responsible for pharmacovigilance activities in that country. 

Depending on the jurisdiction, the MAH may need to appoint a local PV professional or establish a designated local contact responsible for communication with the national competent authority. 

The role may include responsibilities such as: 

• Acting as a point of contact with the national regulatory authority 

• Supporting local safety reporting 

• Ensuring local PV requirements are implemented 

• Monitoring local regulatory changes 

• Supporting inspections and authority requests 

• Facilitating communication between the MAH and local partners 

• Ensuring local PV records are maintained 

• Escalating safety information to the global PV function 

However, companies should avoid assuming that the title or responsibilities of a local PV role are identical across countries. 

A “Local Safety Officer,” “Local Person Responsible for Pharmacovigilance,” “Local PV Contact,” or equivalent role may have different legal expectations depending on the jurisdiction. 

This is why country-specific role mapping is essential. 

The global QPPV or central PV function should also have clear oversight of local activities. The objective is not to create isolated country-level systems, but to establish a connected PV network in which local safety information can move rapidly to the central safety organisation. 

3. Building an Effective ICSR Reporting Process

One of the most operationally demanding aspects of entering a new market is establishing a reliable process for receiving, assessing, processing, and reporting safety cases. 

A company may receive safety information from numerous sources, including: 

• Healthcare professionals 

• Patients and consumers 

• Medical information departments 

• Sales representatives 

• Distributors 

• Market research programmes 

• Patient support programmes 

• Clinical trials 

• Regulatory authorities 

• Published literature 

• Business partners 

• Social media or digital channels, where applicable 

The challenge is therefore not merely how to submit an ICSR, but how to ensure that potentially reportable information is identified and transferred into the PV system without delay. 

The process should clearly define: 

Detection → Receipt → Triage → Validation → Case Processing → Medical Assessment → Quality Control → Regulatory Submission → Follow-up → Reconciliation → Archiving 

Electronic ICSR standards can facilitate harmonisation. For example, FDA currently provides guidance for electronic submission of pre- and post-marketing ICSRs using the ICH E2B(R3) standard. 

However, electronic standards do not eliminate the need to understand local requirements. Reporting channels, timelines, data requirements, follow-up expectations, and submission procedures can differ between jurisdictions. 

A robust market-entry plan should therefore establish a local ICSR reporting matrix specifying: 

For comparison, FDA postmarketing requirements include reporting obligations for certain adverse events, and FDA inspections can assess whether companies maintain complete, accurate, and timely safety information. 

4. Managing Local Safety Agreements and Third Parties

Market expansion frequently involves local partners. 

A pharmaceutical company may work with: 

• Local distributors 

• Commercial partners 

• Licensees 

• Contract research organisations 

• Medical information providers 

• Local PV service providers 

• Importers 

• Manufacturers 

• Affiliates 

• Patient support programme providers 

Each additional party creates another potential route through which safety information may be received. 

This makes Safety Data Exchange Agreements (SDEAs), PV agreements, or equivalent contractual arrangements particularly important. 

A well-designed agreement should clearly define: 

• Scope of products 

• Territories covered 

• PV responsibilities of each party 

• ICSR exchange timelines 

• Serious and non-serious case handling 

• Follow-up responsibilities 

• Literature monitoring 

• Signal management 

• Periodic safety reporting 

• Regulatory authority communications 

• Safety-related complaints 

• Product quality complaints with potential safety implications 

• Reconciliation 

• Training 

• Record retention 

• Audit and inspection rights 

• Escalation procedures 

• Business continuity arrangements 

The objective is to eliminate uncertainty. 

A common weakness in multinational PV systems is the assumption that “someone else is handling it.” Effective agreements replace assumptions with clearly documented responsibilities. 

5. Local Literature Monitoring: A Frequently Overlooked Challenge

Medical literature is an important source of safety information, but literature monitoring requirements may vary significantly between markets. 

A global literature search may identify publications relevant to a company’s products, but some countries may require additional monitoring of national or local-language literature. 

This can create several practical challenges: 

• Identifying relevant local journals 

• Determining which databases should be searched 

• Establishing search strategies in local languages 

• Managing non-English publications 

• Documenting search results 

• Evaluating publications for reportable safety information 

• Maintaining evidence of searches for audit purposes 

The company should therefore determine, for each market: 

1. Whether local literature monitoring is required. 

1. Which journals and databases must be monitored. 

1. Whether searches need to be conducted in the national language. 

1. How frequently searches must be performed. 

1. Who is responsible for screening and assessment. 

1. How results should be documented. 

This should be incorporated into the company’s overall literature surveillance strategy rather than treated as an isolated local activity. 

6. Adapting the Global Risk Management Strategy to Local Requirements

Risk management is another area where global and local requirements must be aligned. 

A Risk Management Plan (RMP) describes known and potential safety concerns and the pharmacovigilance activities and risk-minimisation measures intended to address them. 

For example, in the EU, applicants are required to submit an RMP as part of the marketing authorisation application, and the plan describes existing safety knowledge as well as planned pharmacovigilance activities. 

When entering a new market, the company should assess whether: 

• A local RMP is required 

• The global RMP is accepted 

• Additional national risk-minimisation measures are required 

• Educational materials need local adaptation 

• Additional safety monitoring is required 

• Local epidemiological considerations affect the benefit-risk assessment 

• The national authority requires additional commitments 

This becomes particularly important when a product has specific risks that may require additional monitoring or educational measures. 

The principle should be: 

Global consistency + local regulatory compliance. 

7. Periodic Safety Reporting and Ongoing Benefit-Risk Evaluation

Market entry does not end the company’s PV responsibilities. 

Once a medicine is marketed, safety information continues to accumulate. Companies must therefore maintain processes for periodic evaluation of the product’s safety profile and benefit-risk balance. 

Depending on the jurisdiction and product, this may involve: 

• Periodic Safety Update Reports (PSURs) 

• Periodic Benefit-Risk Evaluation Reports (PBRERs) 

• Development Safety Update Reports (DSURs) 

• Local periodic reports 

• Ad hoc safety assessments 

• Regulatory responses 

• Signal evaluations 

The exact requirement and reporting frequency depend on the product, authorisation status, jurisdiction, and applicable legislation. 

The EU, for example, identifies PSURs, signal management, risk management plans, risk-minimisation measures, PASS, and other activities within its post-authorisation pharmacovigilance framework. 

For a company operating across multiple markets, the challenge is coordinating these requirements without creating conflicting processes. 

A central regulatory calendar should therefore map: 

Product → Country → Report Type → Data Lock Point → Submission Deadline → Responsible Person → Submission Method → Confirmation/Proof of Submission 

8. Signal Detection in a Multinational Environment

A safety signal identified in one country may have implications for patients worldwide. 

For example, a local increase in reports may reflect: 

• A genuine safety signal 

• Differences in prescribing patterns 

• Increased awareness of an adverse event 

• Changes in reporting behaviour 

• A local formulation or manufacturing issue 

• A specific patient population 

• A local medication-use pattern 

Therefore, local PV teams should have mechanisms to escalate potential signals to the global PV function. 

The global safety organisation can then assess whether the observation represents: 

• A local issue 

• A regional issue 

• A global signal 

• A reporting artefact 

• A known risk requiring continued monitoring 

This is where effective communication between local PV personnel and the global safety team becomes critical. 

9. Regulatory Intelligence: Keeping Up With Changing Requirements

One of the biggest challenges of international expansion is that pharmacovigilance requirements are not static. 

Regulatory authorities continuously update: 

• PV legislation 

• Guidelines 

• Reporting portals 

• Electronic submission requirements 

• Local contact requirements 

• Safety reporting timelines 

• Templates 

• Risk management requirements 

• Inspection expectations 

• Data privacy requirements 

For this reason, regulatory intelligence should be integrated into the PV operating model. 

A strong regulatory intelligence process should include: 

Monitor → Assess → Document → Implement → Train → Verify 

When a new requirement is identified, the company should determine: 

1. Does it apply to the product? 
2. Does it apply to the MAH? 
3. Does it require a change to an SOP? 
4. Does it affect an existing agreement? 
5. Does it require a regulatory submission? 
6. Does it require staff training? 
7. Is a gap assessment necessary? 
8. When must compliance be achieved? 

The purpose is not simply to know that a regulation has changed. The real objective is to translate regulatory change into operational action. 

10. Pharmacovigilance Inspections: Preparing From Day One

A new market should be approached with the assumption that the PV system may eventually be inspected. 

Regulatory authorities may evaluate whether the MAH has established an effective PV system and whether activities are being performed according to applicable legislation and internal procedures. 

EMA, for example, states that MAHs are responsible for ensuring compliance with applicable EU standards and that pharmacovigilance inspections are part of the regulatory oversight framework. 

Inspection readiness should therefore include: 

• Current SOPs 

• Clearly defined responsibilities 

• Training records 

• ICSR documentation 

• Submission evidence 

• Reconciliation records 

• Literature search documentation 

• Signal evaluation records 

• Safety agreement documentation 

• Regulatory correspondence 

• CAPA records 

• Audit records 

• Vendor oversight documentation 

• Business continuity plans 

A useful principle is: 

If an activity is important enough to perform, it is important enough to document. 

Inspection readiness should not be a project initiated immediately before an inspection. It should be embedded into everyday PV operations. 

11. Data Privacy, Technology, and Cross-Border Data Transfer

Global pharmacovigilance increasingly depends on electronic systems and international data exchange. 

When safety information is transferred between countries, companies must consider not only PV requirements but also applicable data protection and privacy requirements. 

Key considerations may include: 

• Patient identifiers 

• Reporter information 

• Data minimisation 

• Access controls 

• Secure data transfer 

• Retention periods 

• Vendor access 

• Cross-border transfers 

• Database security 

• Data integrity 

Technology can significantly improve PV efficiency, but it also creates new compliance considerations. 

A company expanding into multiple markets should therefore ensure that its safety database, reporting tools, document-management systems, and communication channels can support the relevant jurisdictions while maintaining appropriate controls. 

12. Training and Awareness Across the Organisation

A pharmacovigilance system cannot rely exclusively on the PV department. 

Employees outside PV may become the first recipients of safety information. 

For example, a sales representative may receive a patient complaint, a medical representative may hear about an adverse event, or a customer-service employee may receive a safety-related telephone call. 

These employees need to understand: 

• What constitutes safety information 

• How to recognise a potential adverse event 

• Who should receive the information 

• How quickly it must be forwarded 

• What information should be captured 

• What they should and should not communicate to the reporter 

Third parties also require appropriate training where they have PV responsibilities. 

Training should therefore be role-based, documented, and refreshed periodically. 

13. Building a Scalable PV Model for Multiple Markets

A company entering one new country may initially manage PV activities through a small local team. However, expansion into several countries can quickly create a complex network of local requirements. 

A scalable PV model should establish three interconnected levels: 

Global Level 

Responsible for: 

• Overall PV strategy 

• Global safety database 

• Signal management 

• Global benefit-risk assessment 

• Global safety governance 

• Core PV procedures 

• Global regulatory strategy 

Regional Level 

Responsible for: 

• Coordination between countries 

• Regional oversight 

• Harmonisation of local processes 

• Regulatory intelligence 

• Performance monitoring 

• Escalation management 

Local Level 

Responsible for: 

• National regulatory requirements 

• Local authority communication 

• Local reporting 

• Local literature monitoring, where applicable 

• Local PV contacts 

• Local training 

• Country-specific documentation 

This structure allows companies to maintain consistency without ignoring local requirements. 

14. A Practical Market-Entry Pharmacovigilance Checklist

Before launching a product in a new country, companies should consider completing the following checklist: 

Regulatory 

• Identify the national competent authority. 

• Review applicable PV legislation and guidelines. 

• Identify local PV reporting requirements. 

• Confirm reporting timelines. 

• Identify required local PV personnel or contacts. 

• Confirm regulatory submission routes. 

Operational 

• Establish local ICSR intake and reporting procedures. 

• Define escalation pathways. 

• Establish local literature monitoring where required. 

• Define follow-up procedures. 

• Establish reconciliation processes. 

• Ensure appropriate record retention. 

Agreements 

• Identify all third parties involved in the product lifecycle. 

• Establish or update PV/SDEA agreements. 

• Define responsibilities and timelines. 

• Establish audit and inspection provisions. 

Risk Management 

• Review RMP requirements. 

• Identify additional risk-minimisation measures. 

• Assess local safety concerns. 

• Establish monitoring commitments. 

Quality 

• Implement applicable SOPs. 

• Complete training. 

• Establish quality oversight. 

• Maintain inspection readiness. 

• Define CAPA processes. 

Technology and Data 

• Confirm safety database capabilities. 

• Confirm electronic reporting requirements. 

• Assess data privacy requirements. 

• Establish secure data-transfer mechanisms. 

Conclusion 

Expanding into a new pharmaceutical market is not simply about obtaining a marketing authorisation. It is about establishing a sustainable system capable of continuously monitoring the safety of the medicine once it reaches a new patient population. 

The complexity arises from the interaction between global pharmacovigilance standards and local regulatory expectations. A successful market-entry strategy should therefore integrate pharmacovigilance from the beginning, covering local regulatory requirements, responsibilities, ICSR reporting, literature monitoring, safety agreements, risk management, periodic reporting, signal detection, regulatory intelligence, training, data protection, and inspection readiness. 
 
For pharmaceutical companies preparing to enter a new market, having the right pharmacovigilance and Regulatory Affairs support can help turn these requirements into a practical and sustainable operating model. Baupharma supports pharmaceutical companies in navigating the Pharmacovigilance and Regulatory requirements associated with market expansion, from assessing local requirements and establishing PV processes to supporting safety reporting, signal management, risk management, regulatory intelligence, compliance monitoring, and inspection readiness. 

By connecting local regulatory requirements with global pharmacovigilance systems, Baupharma helps companies build a consistent and scalable approach to market expansion while maintaining appropriate oversight of their safety and regulatory obligations. 

As the WHO emphasises, pharmacovigilance remains essential because clinical trials cannot fully predict how medicines will perform across the broader and more diverse populations encountered after authorisation. 

Ultimately, effective pharmacovigilance is not a barrier to international expansion. It is one of the foundations that makes sustainable expansion possible. 

Key Takeaways 

• Market expansion requires local PV assessment: Global PV procedures may need to be adapted to national requirements. 

• Responsibilities must be clearly defined: The roles of the MAH, global PV team, local PV personnel, affiliates, distributors, and service providers should be documented. 

• ICSR reporting must be operationally robust: Intake, assessment, submission, follow-up, and reconciliation processes should be established before launch. 

• Local requirements matter: Literature monitoring, reporting channels, languages, timelines, local contacts, and risk-management obligations can differ between markets. 

• PV agreements are critical: Third-party responsibilities and safety-data exchange timelines should be clearly documented. 

• Regulatory intelligence is essential: Companies must continuously monitor changes in national legislation and guidance. 

• Inspection readiness starts on Day One: Documentation, training, quality systems, and evidence of compliance should be maintained from the beginning. 

• PV should be scalable: A well-designed global, regional, and local operating model can support expansion into multiple markets without compromising compliance. 

• Patient safety remains the ultimate objective: Pharmacovigilance enables companies and regulators to continuously evaluate and manage the benefit-risk profile of medicines in real-world use.